Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly (3ECog)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The world population has reached an unprecedented seven billion, with global population ageing increasing at a greater rate than total population growth. Between 1998 and 2030, the proportion of persons aged 65 years and over in Singapore will grow by about 3% annually compared to 1.0-1.3% in some developed nations. Specific cognitive deficits like inattention, dysexecutive functioning, and processing speed decline may affect a number of quality of life domains. Concurrent with these statistics, the maintenance of the highest possible level of cognitive functioning for as long as possible has become an important goal of aging successfully.
To contribute to the realization of this goal we propose to conduct a wait-list control pilot trial to examine the efficacy and safety of BrainpalTM for cognitive enhancement in the normal elderly. BrainpalTM uses a technology which analyzes brain waves captured through an electroencephalogram to determine the participants' state of attention. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
BrainpalTM may represent one alternative means to enhance cognitive abilities and to slow down cognitive decline in the normal elderly. If demonstrated to be efficacious, this therapy may even help to delay the onset of dementia.
In addition, the rate of cognitive decline during the course of AD is possibly influenced by not only environmental but also genetic factors. To date, several genes, such as apolipoprotein E (APOE) and TOMM40 (translocase of outer mitochondrial membrane 40 homologue), have been identified to be probable genetic risk markers for AD. These genes have been shown to play a role in disease onset as well as rates of cognitive decline. For instance, studies have shown APOEε4 allele carriers to be associated with earlier and faster cognitive decline.
Therefore, we propose to analyse if there is any relationship between the genetic profiles of our participants and their performance in the BrainpalTM training program.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Singapore, Singapour, 169857
- Duke-NUS Graduate Medical School
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age range between 60-70 years old
- Clinical Dementia Rating (CDR) of 0.5*
- Geriatric Depression Scale (GDS) of 9 and below
- Mini-Mental State Examination of 24 and above*
- Chinese ethnicity
- Literate in English and/or Chinese
Able to travel to study site independently
- In the case of conflicting CDR and MMSE scores, MMSE scores will supersede CDR scores.
Exclusion Criteria:
- Any known neuropsychiatric disorders (such as epilepsy or mental retardation)
- Involvement in another research study (aside from SLAS)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Intervention
Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks.
Each session will take 30-minute to complete.
The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
|
Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device.
It is a technology that enables people to interact with computers through their thoughts.
Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication.
The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity.
The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
Autres noms:
|
|
Aucune intervention: Wait-List Control
The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards.
They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Délai: Comparison in the change of RBANS total score from baseline (Week 1) to post-treatment (Week 8) in Intervention Group versus Wait-List Control group
|
The Total Score on RBANS reflects the neurocognitive status of the participant by summing five index/domain scores.
The domains are Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory.
|
Comparison in the change of RBANS total score from baseline (Week 1) to post-treatment (Week 8) in Intervention Group versus Wait-List Control group
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Adverse Events reported by participants on the Safety Measurement Form
Délai: The duration of 8 weeks of intensive BCI intervention sessions
|
The Safety Measurement Form will be completed at the start of every BCI intervention visit (except the first visit).
It will collect information on any safety concerns and/or side effects experienced by the participant since their last BCI intervention visit.
|
The duration of 8 weeks of intensive BCI intervention sessions
|
|
Usability Measurement
Délai: Before a subject exits from the study, including completion of the protocol and withdraw of consent
|
The usability measurement collects feedback on the acceptability and usability of the BCI intervention program to improve user satisfaction in future trials.
|
Before a subject exits from the study, including completion of the protocol and withdraw of consent
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Relationship between genetic profile of participants and their performance on the BrainpalTM training program
Délai: After the BrainpalTM training program is completed
|
Blood samples will be collected from each subject for DNA extraction.
The samples will be used to generate a genetic profile for each subject.
The presence or absence of genes of interest (i.e.
TOMM40 and APOEε4)on a subject's genetic profile will then be associated with his or her corresponding performance on BCI, as measured by his or her RBANS scores.
|
After the BrainpalTM training program is completed
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Tih Shih Lee, MD, PhD, Duke-NUS Graduate Medical School
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 11-363
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .